Related Experiment Video

Updated: May 18, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Nasal and bronchial airway epithelial cell mediator release in children

Emily J Pringle1, Helen B Richardson, David Miller

  • 1Child Health, University of Aberdeen, Aberdeen, UK.

Pediatric Pulmonology
|October 2, 2012
PubMed

Insights

Nasal airway epithelial cells (AEC) release more IL-6, IL-8, and G-CSF than bronchial AEC in children. Nasal AEC can substitute for bronchial AEC in some pediatric studies, but bronchial AEC are preferred.

Area of Science:

  • Pediatric respiratory research
  • Airway inflammation and immunology
  • Cellular mediator release

Background:

  • Airway epithelial cells (AEC) play a crucial role in immune responses.
  • Understanding mediator release from upper and lower airway AEC in children is important for respiratory health studies.
  • Previous research has not fully compared mediator release profiles between nasal and bronchial AEC in pediatric populations.

Purpose of the Study:

  • To test the hypothesis that airway epithelial cell (AEC) mediator release is similar in upper and lower airways of children.
  • To compare the release of specific inflammatory mediators from nasal and bronchial AEC in pediatric subjects.
  • To evaluate the potential of nasal AEC as a surrogate for bronchial AEC in pediatric research.

Main Methods:

  • Nasal and bronchial AEC were collected via brushing from children undergoing general anesthesia.
  • The release of multiple mediators, including interleukins (IL-6, IL-8), G-CSF, RANTES, MCP-1, VEGF, MMP-9, and TIMP-1, was quantified.
  • AEC were stimulated with IL-1β and TNF-α to assess mediator release under inflammatory conditions.

Main Results:

  • Significantly higher release of IL-6, IL-8, and G-CSF was observed from nasal AEC compared to bronchial AEC.
  • No significant differences in the release of RANTES, MCP-1, VEGF, MMP-9, and TIMP-1 were found between nasal and bronchial AEC.
  • Stimulation with IL-1β and TNF-α increased mediator secretion from both cell types, with nasal AEC maintaining higher IL-6 and G-CSF release.

Conclusions:

  • Nasal AEC may serve as a viable surrogate for bronchial AEC in pediatric studies investigating RANTES, MCP-1, TIMP-1, and MMP-9.
  • Bronchial AEC remain the gold standard for studying these mediators in children.
  • Differences in IL-6, IL-8, and G-CSF release highlight distinct roles of upper and lower airway epithelium in pediatric immune responses.
Abstract

More Related Videos

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells12:08

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells

Published on: March 10, 2016

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...